Renexxion Ireland Ltd: Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients

ROSCREA, Ireland, Jan. 10, 2023 /PRNewswire/ - Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet

Related Keywords

Ireland ,Roscrea ,North Tipperary ,Irish ,Dhiren Patel ,Kostenloser Wertpapierhandel ,Peter Milner ,Catherine Pearson ,Gastroenterology At Stanford University School Of Medicine ,Drug Administration ,Cf Foundation ,Louis University School Of Medicine ,Renexxion Ireland Limited ,Renexxion Ireland ,Ireland Limited ,Investigational New Drug ,Opinion Leaders ,Zachary Sellers ,Assistant Professor ,Stanford University School ,Associate Professor ,Louis University School ,Greater Europe ,Renexxion ,Nnounces ,Opening ,Investigational ,Drug ,Application ,Aronapride ,Treatment ,Gastrointestinal ,Ysmotility ,Ystic ,Ibrosis ,Patients ,